SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (128)7/8/2002 12:46:18 PM
From: Jim Oravetz  Read Replies (1) of 138
 
Hollis-Eden:HE2000 Boosts Immunity Cell Types In HIV Patients
DOW JONES NEWSWIRES

SAN DIEGO -- Hollis-Eden Pharmaceuticals Inc. (HEPH) said data from a Phase II clinical trial for its investigational immune regulating hormone include beneficial effects on a number of cell types associated with improving immunity in HIV-infected patients as well as a reduction in HIV viral burden in these patients.

The preliminary results are from a placebo-controlled trial in 24 HIV-infected patients who weren't treated before enrolling in the study.

Patients received three cycles of daily subcutaneous injections for five consecutive days of either a 50 mg or a 100 mg dose of HE2000 or placebo every six weeks and were followed for an additional 12 weeks after the last dosing cycle.

In a press release Monday, the company said administration of HE2000 was generally well tolerated by patients in this study, with no drug-related serious adverse events reported.

HE2000-treated patients experienced increases in a number of cell types associated with innate and adaptive cell-mediated immunity, including killer cells, dendritic cells and Th1 cells.

In addition, an analysis performed on eight patients in the study indicated new HIV gag specific T-cell responses were induced after the second treatment course in four out of six patients treated with HE2000, and these responses were not seen in the two placebo treated patients.

The results are being presented at the 14th World AIDS Conference in Barcelona.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News